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Abstract
Background: Mycobacterium avium subspecies paratuberculosis (MAP) causes a chronic wasting
diarrheal disease in ruminants called Johne's disease, that is evocative of human inflammatory bowel
disease (IBD). Agents used to treat IBD, called "anti-inflammatories", immuno-modulators" and
"immuno-suppressants" inhibit MAP growth in culture. We concluded that, unknowingly, the
medical profession has been treating MAP since sulfasalazine's introduction in 1942. Monensin,
called a "Growth Enhancer" in cattle, ameliorates Johne's disease without a documented
mechanism of action. We hypothesized that Monensin would inhibit MAP in culture.
Methods: Using the radiometric 14CO2 Bactec® system, that expresses mycobacterial growth in
arbitrary growth index (GI) units, we studied the effect of Monensin on the growth kinetic of MAP
isolated from humans with IBD ("Dominic", "Ben" & UCF-4) and cattle with Johne's disease (303 &
ATCC 19698.) Results are expressed as percent inhibition of cumulative GI (%–ΔcGI).
Results: The positive control Clofazimine inhibits every strain tested. The negative controls
Cycloheximide & Phthalimide, have no inhibition on any MAP strain. Monensin has dose dependent
inhibition on every MAP strain tested. The most susceptible human isolate was UCF-4 (73% – ΔcGI
at 1 μg/ml) and bovine isolate was 303 (73% – ΔcGI at 4 μg/ml.) Monensin additionally inhibits M.
avium ATCC 25291 (87% – ΔcGI at 64 μg/ml) & BCG (92% – ΔcGI at 16 μg/ml).
Discussion: We show that in radiometric culture the "Growth Enhancer" Monensin causes dose
dependent inhibition of mycobacteria including MAP. We posit that the "Growth Enhancer" effect
of Monensin may, at least in part, be due to inhibition of MAP in clinical or sub-clinical Johne's
disease.
Background
In ruminants worldwide Mycobacterium avium subspecies
paratuberculosis (MAP) causes Johne's disease [1], which is
evocative of inflammatory bowel disease (IBD) in
humans [2]. As of 2007, 68% of all US cow herds had at
least one environmental sample that cultured positive for
MAP, rising to 95% in herds of > 500 cows [3]. The finan-
cial cost of Johne's disease to the agricultural industry, in
the USA alone, is estimated to be > $200 million a year.
Humans are continually exposed to viable MAP, as MAP
has been cultured from commercially available pasteur-
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ized milk in the US [4], and Europe [5] and is found in
potable chlorinated municipal water in the US [6] and
Europe [7]. Although controversial, there is mounting
concern [8] and increasingly compelling data that MAP
may be zoonotic. [9,10] Recently, the agents 5-ASA [11],
azathioprine [12], 6-MP [12,13], methotrexate [13],
cyclosporine A, [14] Rapamycin [14] and Tacrolimus [14],
that are referred to as "anti-inflammatory" "immuno-
modulator" and "immunosuppressants" by physicians,
have been shown to cause dose dependent inhibition of
MAP in culture. Corroborative evidence that MAP may be
zoonotic are that, in humans, the most potent "antiMAP"
agents in culture [12-14], actually clear MAP DNA from
the blood of individuals with Inflammatory Bowel Dis-
ease [15]. We suggested [11,13,14] that, unknowingly, the
medical profession had been treating MAP since 1942,
when Nana Svartz introduced sulfasalazine into clinical
practice [16].
Introduced in 1967, Monensin [17] is acknowledged as an
anti-coccidicidal agent for poultry [18-20]. Approved as a
"Growth Enhancer" antibiotic in the USA, the UK and
Europe [21], Monensin accounts for 13% of the total sub-
therapeutic livestock antibiotic usage in the USA [22].
Eukaryotic metabolic effects of Monensin, include inhibi-
tion of endosome acidification [23] Na+ ionophore
enhancement [24] including action on Leishmania dono-
vani. [25] and possibly prokaryotes [23,26]. In ruminants
the administration of Monensin results in improved
energy balance [27], decreases methanogenesis [28],
increases plasma urea-N [29], and increased milk produc-
tion in lactating cows [30]. It is of considerable interest
that the use of Monensin results in amelioration of
pathology [21,31-33] and results in clinical improvement
in animals with Johne's disease [34,35].
We hypothesized that Monensin, in addition to its pro-
tean anti-coccycidal [18-20] and eukaryotic effects [23-
25,36] may additionally inhibit prokaryotes [26], in par-
ticular MAP. If correct, ruminant "Growth Enhancement"
may in part be consequent to "antiMAP" antibiotic activ-
ity in cattle with clinical or sub-clinical Johne's disease. To
test this hypothesis, we studied the effect of Monensin on
mycobacteria including M. avium and its subspecies
paratuberculosis, using our previously validated culture
inhibition methods [11,13,14].
Methods
This study was conducted as an approved protocol of the
Research and Development Committee of the VAMC
Bronx approved protocol (0720-06-038.) Inhibition stud-
ies were performed on eight mycobacterial strains in cul-
ture, as reported. [11,13,14] Five strains were MAP, of
which three were isolated from humans with IBD,
"Dominic" (ATCC 43545), Ben, (ATCC 43544) [37] &
UCF-4 (gift of S. Naser Orlando FL.) Two were MAP
bovine isolates, ATCC 19698 (ATCC Rockville MD) & 303
(gift of M. Collins. Madison WI) [38]. The M. avium sub-
species  avium  strains (subsequently referred to as M.
avium) were ATCC 28291 (ATCC) and M. avium 101 [39].
To study the effect on the M. tuberculosis complex we used
a Biosafety level II surrogate, BCG M. bovis Karlson & Les-
sel (ATCC 19015.) Agents (all from Sigma, St Louis MO)
were dissolved in DMSO [11,13] with a final concentra-
tion in every Bactec vial, irrespective of the amount of
agent in a vial, of 3.2% DMSO.
Quantifying mycobacterial growth and the effect of agents
tested, using the radiometric 14CO2 Bactec 460 system, has
previously been reported in detail [11,13,14]. In brief, the
daily Growth Index (GI) for each vial is obtained until any
vial reaches the instrument maximum of GI of "999."
Daily GI's are summated until the day prior to any vial
reaching "999." The effect (or lack thereof) of each agent
is presented as the percent decrease in cumulative Growth
Index (cGI) units (% – ΔcGI) ± SD [11] (when necessary,
see individual figures).
Results
For ease of comprehension, data are presented in two
ways: For individual mycobacterial strains, data are pre-
sented as Figures using the cumulative Growth Index
(cGI). For individual chemicals the same data, recalcu-
lated as %–ΔcGI [11,13], are presented as Tables. Figure 1
= MAP isolated from humans with Crohn's Disease. Fig-
ure 2 = Bovine Isolates of MAP from animals with Johne's
disease. Figure 3 is M. avium subspecies avium. Figure 4
presents data for BCG. Table 1 is the positive antibiotic
control Clofazimine (used in leprosy [40] and clinical tri-
als of Crohn's disease [41,42].) The negative controls are
the gluterimide antibiotics cycloheximide (Table 2) and
phthalimide (Table 3.) The study results on Monensin are
presented in Table 4.
In total we performed 29 culture inhibition experiments
that included Monensin, of which 21 involved MAP that
had been isolated from either ruminants or humans. In
every case where Monensin was studied for its effect on
MAP, dose dependent inhibition was observed. For brev-
ity and clarity, representative studies are presented. The
positive control, clofazimine causes dose dependent inhi-
bition; > 98% – ΔcGI in every strain tested by 1 μg/ml
(Figures 1, 2, 3, 4 & Table 1.) A negative control Cyclohex-
imide has no inhibition on any MAP strain at the doses
used in these studies (Figures 1 &2 & Table 2.) In contrast,
when tested against M. avium ATCC 25291, Cyclohex-
imide has no effect between 1 & 16 μg/ml, but does have
57% – ΔcGI at 64 μg/ml (Figures 3 & Table 2.) Similarly,
against BCG, Cycloheximide has no dose dependent inhi-
bition between 1 & 16 μg/ml, but does have 78% – ΔcGI
at 64 μg/ml (Figures 4 & Table 2.) Phthalimide, the other
negative control, has no dose dependent inhibitionGut Pathogens 2009, 1:4 http://www.gutpathogens.com/content/1/1/4
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against any of the eight mycobacterial strains evaluated
(Figures 1, 2, 3, 4 & Table 3.)
Monensin exhibits dose dependent inhibition on MAP in
culture, whether isolated from humans with Crohn's dis-
ease (Figure 1 & Table 4) or cows with Johne's disease
(Figure 2 & Table 4.) Of the human MAP isolates, UCF-4
was most susceptible, 73% – ΔcGI at 1 μg/ml (Figure 1 &
Table 4) and Ben least inhibited (51% – ΔcGI at 4 μg/ml:
Figure 1 & Table 4.) Of the two bovine MAP isolates,
ATCC 19698 (45% – ΔcGI at 4 μg/ml) was less inhibited
than 303 (73% – ΔcGI at 4 μg/ml: Figure 2 & Table 4.)
Monensin additionally causes dose dependent inhibition
on two of the three control mycobacterial strains; ATCC
25291 & BCG (Figures 3 &4 & Table 4.) The single excep-
tion to inhibition by Monensin is with the control M.
avium subspecies avium strain 101 (Figure 3 & Table 3.)
Discussion
The "anti-inflammatories" "immune-modulators' and
"immune-suppressants" 5-ASA [11], azathioprine [12], 6-
MP [12,13], methotrexate [13], cyclosporine A, [14]
Rapamycin [14] and Tacrolimus [14], all cause dose
dependent inhibition of MAP in culture. We suggest that,
unlike the majority of antibiotics, which effect only
prokaryotes, these agents inhibit both pro and eukaryotes.
It is therefore possible that these terms "anti-inflammato-
ries" "immune-modulators' and "immune-suppressants"
are actually misnomers. We suggest that these appella-
tions merely report normal secondary eukaryotic physio-
logical effects, consequent to, unknowingly, treating an
underlying prokaryotic infection. Specifically we suggest
that since 1942, the medical profession has unknowingly
been treating MAP infections when using these medica-
tions.
Our present data corroborate the culture finding of Brum-
baugh et. al. [33]. With a single strain of MAP, in one cul-
ture experiment, there was no visually detectable growth
at 30 days following inoculation. This was interpreted as
showing a Monensin Minimum Inhibitory Concentration
of 0.39 μg/ml against MAP. In our study, a distillation of
29 different experiments involving Monensin, of which
21 were conducted against five strains of MAP, we show
presents data for the three human isolates of MAP from patients with Crohn's disease Figure 1
Presents data for the three human isolates of MAP from patients with Crohn's disease. All three have dose 
dependent inhibition, albeit to varying degrees for Dominic, UCF-4 and Ben. Error bars are ± SD.Gut Pathogens 2009, 1:4 http://www.gutpathogens.com/content/1/1/4
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that, in radiometric culture, Monensin causes dose
dependent inhibition of MAP, one of two strains of M.
avium subspecies avium and a single strain of M. Bovis.
The fact that MAP is the etiological agent in Johne's dis-
ease is uncontested. There have been a plethora of obser-
vation studies on the "metabolic" effects [26,28-30] when
Monensin is used in cattle. Monensin is called a "Growth
Enhancer" by both veterinarians as well as governmental
agencies [21]. These culture inhibition studies offer a
rational explanation for the healing of Johne's lesions
[31,32] in ruminants with Johne's disease treated with
Monensin. As mean prevalence of MAP in US dairy herds
steadily increases, currently 68%, [3] it is probable that
some of these observations were, unknowingly, made on
animals with sub-clinical Johne's disease. We posit that at
least some of the "Growth Enhancement" as well as met-
abolic effects that attends the use of Monensin in rumi-
nants may be the physiological consequence of treating
overt or covert MAP infections.
A plausible question is whether the appropriate use of
antiMAP agents "cures" Johne's disease? The dose depend-
presents the dose dependent inhibition data for Monensin on  isolates of MAP from cows with Johne's disease, ATCC  19698 and 303 Figure 2
Presents the dose dependent inhibition data for Mon-
ensin on isolates of MAP from cows with Johne's dis-
ease, ATCC 19698 and 303. Error bars are ± SD.
Shown are the data from two Control strains, M. avium  ATCC 25291 (Bovine source) and 101 [39] Figure 3
Shown are the data from two Control strains, M. 
avium ATCC 25291 (Bovine source) and 101 [39]. 
Note that Monensin, uniquely in this study has no dose 
dependent inhibition on M. avium subspecies avium 101.
With BCG, our Biosafety level II surrogate for the M. tubercu- losis complex, Monensin exhibits doses dependent inhibition Figure 4
With BCG, our Biosafety level II surrogate for the M. 
tuberculosis complex, Monensin exhibits doses 
dependent inhibition.Gut Pathogens 2009, 1:4 http://www.gutpathogens.com/content/1/1/4
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ent inhibition of Monensin that we demonstrate, are com-
patible with Monensin being a bacteriostatic, rather than
bactericidal antiMAP agent. Our data are therefore com-
patible with the observations that the use of Monensin
ameliorates [32], but does not eradicate or clear MAP
from animals with Johne's disease [31,33]. This would
render Monensin analogous to another "antiMAP" agent,
5-ASA where the effect is demonstrably bacteriostatic [11].
In our culture system Monensin is not nearly as inhibitory
as methotrexate and 6-MP [12,13], which clear MAP DNA
from the blood of individuals with Inflammatory Bowel
Disease [15]. We conclude that Monensin cannot be con-
sidered as a "cure" for a ruminant MAP infection.
This study does not address the inhibitory mechanism of
Monensin on MAP. One possibility is that it is consequent
to cell wall destruction, as occurs with coccidia [18]. Alter-
natively Monensin's antiMAP activity may be due to per-
turbation of obligate intracellular metabolic pathways
such a DNA synthesis, as occurs with Methotrexate and 6-
MP. Distinguishing between the two modes of action is
important. In man, MAP exists in the cell wall deficient
form (see [10] for review). In contrast, in ruminants it is
the cell wall containing form of MAP that is readily iden-
tified [1]. We conclude that our present observations do
not justify initiating human clinical trials of Monensin in
putative zoonotic MAP infections such as Crohn's disease
or ulcerative colitis. Such appropriately planned and
Table 1: Positive control
Clofazimine
%–ΔcGI
Clofazimine MAP M. avium M. bovis
μg/ml Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 303 25291 101 19015
1 -99% -99% -99% -99% -99% -98% -98% -99%
4 -99% -99% -99% -99% -99% -98% -98% -98%
16 -99% -99% -99% -99% -99% -98% -98% -98%
64 -99% -99% -99% -99% -99% -99% -99% -99%
Data are presented for a single agent, Clofazimine, the positive antibiotic control. Data are given for a representative experiment of each 
mycobacterial strain studied. Note maximal inhibition at 1 μg/ml. for every strain. %–ΔcGI = Percent decrease in cumulative Growth Index 
compared to solvent control (see Methods.)
Table 2: Negative Control
Cycloheximide
Cycloheximide MAP M. avium M. bovis
μg/ml Human Bovine Bovine BCG
Dominic UCF-4 Ben 19698 303 25291 101 19015
1 15% 1% 7% -2% 3% 0% 6% -12%
4 -4% -7% 1% -7% 4% -8% 7% -13%
16 -8% -4% -3% -12% -5% -7% 1% -8%
64 -1% -12% -5% -9% -4% -57% 5% -78%
Data are presented for a single agent, the gluterimide antibiotic Cycloheximide, a negative antibiotic control. Data are given for a representative 
experiment of each mycobacterial strain studied. Note that there is no strain exhibiting dose dependent inhibition within the range tested. %–ΔcGI 
= Percent decrease in cumulative Growth Index compared to solvent control (see Methods.)Gut Pathogens 2009, 1:4 http://www.gutpathogens.com/content/1/1/4
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authorized human trials should only be performed if the
antiMAP action of Monensin is unequivocally shown to
affect intracellular metabolic pathways of MAP and not its
cell wall.
Abbreviations
MAP: Mycobacterium avium subspecies paratuberculosis;
IBD: inflammatory bowel disease; GI: Growth Index; cGI:
cumulative Growth Index; % – ΔcGI: percent decrease in
cGI units compared to control growth.
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